Deloitte today announced it has acquired substantially all
of the assets of Intrasphere Technologies, Inc., a global drug safety and
regulatory consulting business. Terms of the deal were not disclosed.

Headquartered in Jersey City,
New Jersey, with its European headquarters in London, Intrasphere
provides professional services to help life sciences companies improve product
safety, signal intelligence, pharmacovigilance and regulatory information
management capabilities.

The acquired assets include Intrasphere’s PharmaCM, a
software solution that enables life sciences companies to register clinical trial
information on government-mandated registries through the use of workflow-enabled
functionality that allows for simplified content management and re-use. The
PharmaCM product will be provided as a service offering within Deloitte Managed
Analytics, which is led by Richard Cohen, principal, Deloitte Consulting LLP.

The combined capabilities span a broad spectrum of business
and technology solutions in the drug safety market. These solutions focus on
enabling enhanced signal intelligence and analytics through the planning,
design and implementation of drug safety data warehouses, adverse event
management applications, remote data capture tools, and assembly of periodic
reporting for regulatory agencies. As a result, this new business will tap into
Deloitte’s enterprise risk, security and regulatory compliance services, and
additional business advisory services.

“We are excited about this important and strategic
investment,” said Dan Ressler, principal, Deloitte Consulting LLP, who
will lead Deloitte’s new drug safety and regulatory consulting business as part
of his overall responsibilities in leading research and development informatics
in life sciences. “The growing impact of health information technology and
social media, greater complexity of therapeutic offerings in the marketplace,
and an increasingly complex and stringent regulatory environment, in
particular, have created an impetus for more proactive product safety and
regulatory support services.” Ressler added, “The addition of
Intrasphere’s capabilities to the Deloitte portfolio of life sciences
consulting services enhances our position in drug safety and regulatory
consulting and expands the foundation on which we will continue to lead this
market. Intrasphere brings deep proficiencies in drug safety, pharmacovigilance
and regulatory capabilities to complement our existing life sciences and research
and development practice enabling us to expand our ability to create
market-leading strategic solutions for our clients.” Intrasphere’s
existing clientele have the potential to benefit significantly from the
transaction. Deloitte’s life sciences consulting practice features a broad
suite of services ranging from strategy to execution across the life sciences
value chain and global reach through the member firms of Deloitte Touche
Tohmatsu Limited.

“Deloitte’s broad-based relationships in life sciences
give us access to clients where we don’t have a presence today. Moreover, our
staff and leadership now have the opportunity to gain exposure to a variety of
resources and opportunities as part of Deloitte,” said Bill Karl, co-founder
and former chief executive officer of Intrasphere. Karl now joins Deloitte
Consulting LLP as a director.